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Short-course treatment of acute sinusitis with 
moxifloxacin versus cefuroxime-axetil 
R. Sieged, D. Bagger-Sjoback'. P. Gehanno', I? Nikolaidis4, the 
Moxifloxacin Sinusitis Study Group. 'Medizinische Universith't, 
Liibeck, Germany; 'Karolinska Hospital, Stockholm, Sweden; 'Bichat 
Claude-Bernard Hospital, Paris, Frame; 4 A H E P A  University, 
nessnfoniki ,  Greece 
Objectives: To compare the safety and efficacy of moxifloxacin 
(MFX), 400 mg once daily for 7 days, with cefuroxime-axetil (CEF), 
250 mg twice daily for 10 days, in the treatment of acute bacterial 
sinusitis. 
Methods: A total of 498 patients with acute bacterial sinusitis that 
was either bacteriologically documented or clinically suspected on 
the basis of radiologic sinus X-ray and two or more clinical symp- 
toms of acute sinusitis were enrolled in the study A total of 436 
patients (87.5%) were valid for efficacy (PP) analysis, 21 1 MFX and 
225 CEF; 224 patients (51.2%) were microbiologically valid, 109 
MFX and 115 CEF. 
Results: Clinical success rates at end of therapy (EOT) were: 
MFX 96.7%. CEF 90.7% (95% C; I.%%, 10.6%). Bacterial eradica- 
tion: 
The incidence of adverse drug reactions was 31.4% with MFX and 
23.1% with CEF, and discontinuations were similar in both groups. 
Conclusions: The clinical and bacteriologic response at EOT in 
this trial demonstrates that MFX is superior to CEE Both drugs were 
well tolerated. 
lp7221 Incidence of pathogenic microorganisms in 
otics exudates from an extra-hospital 
population 
M.A. Orellana, M. Aramendi, G. Galera, C. Moyano, M.A. 
Amerigo. Department of Microbiolqy, Ambulatorio 'Hermanos Miralles', 
Madrid, Spain 
Objectives: To study retrospectively the microorganisms isolated 
&om otics exudates in the outpatient population living in the south- 
western area of Madrid (Spain). 
Materials and methods: 1255 otics exudates were studied from 
patients aged from 1 month to 91 years, during June 1994 to 
September 1998.The samples were cultured on 5% sheep blood agar, 
chocolate blood agar, broth thioglycollate (subcultured in blood agar 
and chocolate blood agar after 18-24 h), and chloramphenicol- 
gentamicin Sabouraud agar. Bacteria and yeast were identified on the 
microScan System (DADE) and filamentous fungi by microscopic 
exatnination. 
Results: The incidence of positive results was 63.9% (802). Two 
or more microorganisms (10.8%) were isolated from the same samples 
(87). The most frequently isolated microorganisms were: S. aureus 
( 2 8 3 4 ,  I? aerufinosa (23.2%), Candida sp. (16.6%), Aspergillus 
(10.3%), P mirabilis (9.2%), Penicillium (3.0%), E~-rteroburter sp. (1.8%), 
H .  influenzae (l.8%), E. coli (1.5%), Serratia marcescens (1.4%), and 
others (2.7%)). The proportions of microorganisms isolated every year 
were: 19.12% in 1994, 14.72%) in 1995, 25.66% In 1996, 21.37% in 
1997,and 14.72% in 1998. The most frequent microorganism distri- 
bution according to the season was: I? aeruginosa in November; I? 
mirabilis in October, November and February; Candida sp. in 
September; and filamentous fungi in September. 
Conclusions: An elevated proportion of positive cultures was 
found. The most frequently isolated microorganisms were: S. aureus, 
l? aeruginosa, Candida sp., filamentous fungi and l? mirabilis. A high 
proportion of microbial association (2 or more cultures) has been 
found. There was a relationship between the isolated microorganism 
and the season. 
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I P723 I Candida parapsilosis fungemia in cancer 
patients-incidence, risk factors and outcome 
in a single cancer institution within the last 10 
years 
V. Krcmery Jr', J. Trup12, I .  Krupoval, A. Roidova'. 'School of 
Public Health, University of Znava, Znava, 'National Cancer Institute, 
Bratislava, Slovak Republic 
All cases of fungemia caused by C. parapsilosis in a single cancer insti- 
tute within 10 years, in order to compare risk factors and the 
outcome with C. albicans and other non-albicans Candida spp., are 
analyzed. Before 1990 (1988-89) no C. parapsilosis fungemias were 
observed at all. During 1990-96, the proportion of C. parapsilosis 
among fungemias increased from &7.1% in 1990-93 to 14.2-1596 
in 1996-97.This organism therefore represents 25% of non-albicans 
Candida spp. fungemias and 7.9% of all fungemias and is the third 
commonest pathogen after C. albicans (50.5%) and C. krusei (9.9%). 
Two of eight (25%) C. parapsilosis fungemias were breakthroughs; one 
appeared during prophylaxis with ketoconazole, and one with 
fluconazole. According to the univariate analysis, the infected vascu- 
lar catheters were, surprisingly, not the major risk factor, and of 7 
patients of 8 (87.8%) who had the vascular catheter inserted, the 
catheter was documented as the source of fungemia only in 2 cases. 
The commonest determined risk factors were similar to those occur- 
ring with other fungemias-such as previous antimicrobial therapy 
(62.5%). neutropenia (50%) and prior prophylaxis with azoles. 
Comparison of 8 C. parapsiloris fungemias with 51 C. albicans 
fungemias occurring during the same period and in the same insti- 
tute, and with 32 non-albicans Candida spp. in the same period and 
institute and with an identical antifungal policy, showed that there 
were no significant differences in risk factors. Both attributable and 
crude mortality were also similar to C. albicans and non-albicans 
Candida spp. fungemias. 
Candida fungemia in neonates treated with 
fluconazole: report of 40 cases, including 8 
meningitis 
M. Huttovi, V. Krcmery Jr. J. Filka, K. Kralinsky, I .  Hartmanova, J. 
Kurak, J. Fric. Pediatric Clinic, Postgraduate Medical School, Brutislava; 
University of Znava, Znava, Slovak Republic 
Objectives: To assess the efficacy and safety of fluconazole in 
neonates with Candida fungemia. 
Methods: Multicenter prospective protocol of all fungemias 
appearing between 1 January 1993 and 31 December 1997 in four 
major university hospitals. 
Results: Forty neonates, 28 of them with very low birth weight 
(1500 g) (30.5 median gestation week), with documented Candida 
albicans fungemia were treated with intravenous fluconazole at a daily 
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dosage of 6 mg/kg once daily for 6-48 days. Thirty-four received 
fluconazole as monotherapy and 6 in combination with amphotericin 
B. Thirty-two (80%) were cured; however, 4 of them relapsed despite 
at least 14 days of therapy but they were ultimately cured without 
scquelae. Eight other neonates &ed, 4 because offungal infection and 
4 because of prematurity or hemorrhage or lung failure, with 
fungemia (20% overall and 10% attributable mortality). Two neonates 
had elevated liver enzymes during fluconazole therapy and two others 
had elevated serum creatinine during fluconazole nionotherapy. In 
none of them did these abnormalities lead to discontinuation of anti- 
fungal therapy. In 8 neonater, fungal meningitis developed as a 
complication of fungeniia. All but three fungemias were with C. albi- 
cans; 3 were with C. parapsilosis. 
Conclusions: Fluconazole was safe and effective antifungal ther- 
apy even in complicated or candida fungemia in neonates, and also 
in those with very low birth weight. 
lp7251 Activity of the new triazole SCH 56592 in 
combination with amphotericin B,5- 
fluocytosine, itraconazole and fluconazole 
against Candida albicans in suspension and in 
biofilm 
M. EI-Azizi, B. Al-Falaha, A. Shawky, M. Toama, N. Khardori. 
Department of Internal Medicine, School o f  Medicine, Southern Illinois 
Uniuerxity, Springfield, IL, USA; Scliool o j  Pharmacy, Cairo Uniuersity, 
Cairo, Efypt 
Objectives: To study the activity of the new triazole SCH 56592 in 
combination with four antifungal agents against 10 isolates of C.albi- 
cans in wspensions and biofilms. 
Methods: Checkerboard and time kill assays were used to evalu- 
ate the combinations in suspensions. The minimum adherence 
inhibitory concentration, MAICso and MAICxo (minimum concen- 
trations of the drug required to inhibit the adherence by 50% and 
80%) were determined for each drug alone and in combination to 
evaluate the effect on the biofilms. Cultures were suspended and stan- 
dardized using MOPS, and were added to the wells of flat-bottomed 
tissue culture plates containing the drugs to give inoculum sizes of 
0.5-2.5 Y lo’ CFU/mL and drug concentrations of 0.003-1.00 
pg/mL. After 48 h of incubation at 35OC, the contents of the wells 
were aspirated and the biofilins were washed and stained. The excess 
stain was removed and plates were washed and dried in air. The 011 
of the adhered cells w3s measured using a Microplate Reader at 550 
nni; in drug combinations, one drug was added at the mentioned 
concentration, and the other was added at a concentration less than 
the MAICs,,. 
Results: In suspension, the interaction of SCH with the other 
antifungal agents was variable. In the biofilin the MAICxo for SCH 
alone was 0.007 and it was 0.03, 0.03, 0.015 and 0.03 pg/mL in 
combination with AMP, 5FC, I T 2  or FLZ respectively. 
Conclusions: The interaction between the different drugs in 
suspention is variable. In the biofilm the combinations interfere with 
the anti-adherence activity of SCH. 
]p7261 Evaluation of the new chromogenic substrate 
ALBICANS ID 2 (BioMerieux) 
M .  Dioudi, E. Zambeli, M. Nyha, C. Nikolidaki, J. Zannopoulos, 
K. Aggiolina, P. Kostantakos, 0. Kreatsa. Clinical Microbiology 
Central Laboratory, “Mitera” Maternity Hospital, Athens, Greece 
The objective of this study was to evaluate the accuracy of the chro- 
niogenic substrate ALBICANS ID 2 (BioMkrieux) in identi$ing the 
blue-appearing Candida albicans colonies within 24 h. The sample size 
comprised 917 clinical specimens from vaginal and oral infection\. 
Each sample was inoculated onto Sabouraud dextrose agar (SIIA) 
plates and onto ALBICANS ID 2 ready-to-use Petri dishes. All yeasts 
grown on the selective media, including those which appeared blue 
on the chromogenic medium, were also identified by the API ID 
32C (BioMkrieux), in order to confirm identification. 
The results revealed that in 901 clinical samples confluent growth 
was detected within 24 h, whereas in 16 samples, confluent growth 
was achieved in 48 h, even though growth was detectable in 24 h. 
Blue colonies indicative of C. albicans were identified in 728 samples, 
and white colonies, indicative of the presence of Candida non- 
albicans species, were present in 189 samples. All blue colonies grown 
on API ID 32 C showed a carbohydrate assimilation profile compat- 
ible with that of C. albicans. Tuichosporow crrtaneum and C. drr6liniwu.k 
appeared as green colonies on the chromogenic medium. The 
comparative results showed that 55%) and 37%) of the samples gave 
positive growth on SDA within 24 and 48 h respectively, whereas 
91.5% and 8.5% gave positive growth 011 the ALUICANS ID 2 dgar. 
Interestingly enough. 8% of the samples showed growth on SDA 72 
h after inoculation. 
We conclude that the ALBICANS ID 2 is a rapid and reliable 
screening medium for differentiating C .  albicutrs from other yeasts 
within 24 h. 
[p7271 Prevalence and treatment of Candida infection 
in patients with infected pancreatic necrosis 
G. Farkas, J. Mirton, E. Nagy. Department o f S u t p y ,  A. Szent- 
G y b y y i  Medical University, Szeged, Hunyary 
Objectives: To determine the incidence ofcandida infection in cases 
with infected pancreatic necrosis, to determine the most frequent risk 
factors and to assess the best treatment approach for disseminated 
candidal infections. 
Methods: O f  the 145 cases of infected pancreatic necrosis iden- 
tified, 30 (21%) were infected with Candida albicans. Risk factors 
identified in patients with candida infection included the presence of 
necrotic tissue, and the use of broad-spectrum antibiotics, intravan- 
cular catheters and parenteral nutrition. 
Results: With one exception, all cases involved mixed bacterial 
and fungal infections. The positive fungal result was obtained either 
intraoperatively or postoperatively. 16 of the 30 patients displayed 
fungal colonization, whik the other I 4  patientc had disseminated 
fungal infection. There were 2 deaths in the disseminated group, but 
no mortality occurred in the colonization group. In both fatal caTes, 
flucytosine was applied. When fluconazole was used against disscm- 
inated fungal infection, no niortality was noted. Kecently, prophy- 
lactic fluconazole has also been applied in 20 patients with infected 
pancreatic necrosis, without any evidence of fungal infection post- 
operatively 
Conclusions: The combination of adequate surgical treatnient 
with effective antibiotics and early antifungal therapy is the ideal 
management approach for infected pancreatic necrosis with candida 
infection, and prophylactic fluconazole may be regarded a5 an effi- 
cient drug for the prophylaxis of candidiasis. 
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lp7281 Antibody response to Candida albicans in 
hospitalized patients 
K. Themeli-Digalaki, D. Kairis, E. Orcopoulou, C. Koutsia- 
Carousou. Department oJMicrobzologx ‘Asclepeion Voulas’ General 
Hospital, Afhens, Greece 
Objectives: Candida is frequently cultured from mucous membranes 
of hospital patients, but fungal cultures offer little diagnostic help. 
The application of serologic methods may help in the diagnosis of 
invasive candidiasis. The aim of this study was to determine the 
humoral responses by IgM, IgG and IgA niannan isotype against 
specific Candida albicans antigens in hospitalized patients. 
Methods: The patients who were examined (a total of 81 sera) 
were subdivided as follows: group 1, 28 irnmunocompromised 
persons; group 2, 19 intensive care patients with negative cultures for 
Candida; group 3, 24 hospitalized patients with positive cultures for 
Candida; group 4, 10 outpatients as controls (5 children and 5 adults). 
The enzyme immunoassay (EIA) for the detection of IgM and IgG 
antibodes to Candida albicans was used. IgA antibodies against the 
surface mannan antigen of Candida albirans by EIA were determined. 
Results: IgM antibody was detected in 16 patients (20.9%). IgG 
in 16 (32.1%), and IgA in 30 (37.1%). The determination of anti- 
bodies was as follows: IgM 62.5%, IgG 87.5%. and IgA 100%. On 
the other hand, in superficial infections and in colonization, lower 
percentages were observed. The correlation between the anti- 
Candida antibodies and the different Candida species was shown by 
the fact that only one case with Candida tropicalis had positive anti- 
bodies (IgA, IgG) against Candida albicans. 
Conclusions: The findings may be useful in diagnosis of candidi- 
asis. The IgA isotype discriminates between deep-seated and super- 
ficial infections. 
v] Mycologic and clinical characteristics of 
Candida dubliniensis in Berlin, Germany 
M. Ruhnke‘, C. Radecke’, J. Morschhauser‘. ’Charid Campus 
Virchoiu Klinikum, Berlin, ’Universitdt Wurzburg, Germany 
Objectives: Candida dublittiensis is an emerging yeast species which 
has been found in clinical samples primarily from patients with HIV 
infection in some countries in Europe, Australia, and North and 
South America.. A limited number of strains has been described so 
far and epidemiologic data from Germany are rare. 
Methods: During an 8-year period (1990-98) we have detected 
95 C. dubliniensis isolates (1-20 isolates per patient) in oral samples (+ 
one blood culture) from 27 patients (7 female, 20 male; age 9-63 
years) which were individually fo1lowed.with persistent colonization 
for up to 5 years. Underlying disease was HIV infection in 25 patients 
and hematologic malignancies in 2 patients (1 patient with fungemia). 
Results: In all patients another yeast species was found addition- 
ally (mostly C. nlbiram) . In female patients colonized orally, C. 
dubliniensis was not found in vaginal samples. C. dubliniensis was 
simultanously detected together with C. albicans in 4 patients with 
pseudomembranous oral candidosis. The majority of patients carried 
the isolates without symptomatic oral disease. MlCs of fluconazole 
ranged from 0.09 to12.5 pg/mL ( M l C ~ > ~ = 0 . 3 9  pg/mL; 
MICs~,=1.56  pg/mL), and MICs of itraconazole ranged from 0.02 
to1.56 pg/mL. Idenfication with the AP132ID system revealed 3 
different codes (80 isolates had code 7142140015). but 7 codes with 
API2OC. No isolates grew at 45°C. Molecular typing by PCR finger- 
printing (AP-PCR) showed a unique banding pattern, which differed 
clearly from other Cundida species and was uniform for all isolates. 
Sequence analysis of part of the 28s rDNA was used as a confirma- 
tory test for species specificity. 
Conclusions: C. dubliniensis was frequently detected in HIV-posi- 
tive patients, but only rarely in other immunocompromised patients. 
1 P730 I Survey of candidemia cases during the past 5 
years at Moscow pediatric hospitals 
VA. Kurchavov, E.L. Rogahna. Clinical Microbiology Department, 
Moscow Childrens ‘ Center o f  Laboratory Diagnosis, Filatov Pediatric 
Hospital, Moscotu, Rusria 
Objectives: To characterize the epidemiology of candidemia in a 
children’s ICU in the city of Moscow, Russia. 
Methods: We have studied 1382 samples of blood in children’s 
ICUs of nine Moscow children‘s hospitals during the 5-year period 
between 1994 and September 1998. All fungal blood cultures were 
isolated by the routine method. Identification was performed with 
Minitek (Becton Dickinson) and API products (bioMerieux), as 
recommended by the manufacturer. 
Results: Fungi were isolated from 42 cases (3.2%) of 1382 blood 
samples in children froni ICUs of 9 hospitals in Moscow. Only 45.5% 
of the bloodstream infections were due to Candida albicans, 21.2% 
were due to C. parapsilosir, 9.1% were due to C. kmsei, 9.1% were 
due to C. tropicalis, 3% were due to C. glabrata, 3% were due to C. 
guilliermondii, and 9.1% were due to C. pelliculosa. 
Conclusions: This study demonstrates that the increase in the 
frequency of non-C. albicans infections (especially fluconazole-resis- 
tant Candida spp.) over the past 5 years is significant. Thus, the role 
ofaccurate identification and susceptibility testing as a guide in select- 
ing appropriate therapy for all of these infections will increase over- 
all. 
Ip731] Evaluation of Candida ID, a new chromogenic 
medium for yeasts 
S. Orenga, L. Barbaux, C. Cotte, E Doleans, C. Martin, A. 
Rongier. Department of Microbiology, bioMerieux, L.e Zalgnier ,  La 
Balme-les-Grottes, Frartce 
Candida ID (bioMerieux) is a new plated medium for isolation of 
yeasts, identification of Candida albicans (blue colonies), improved 
detection of mixed cultures and pre-identification of other species 
(C. tropicalis, C. guilliermondii, C. kefyr and C. Iusitaniae, pink colonies) 
by means of two enzymatic activities and a specific inhibitor of the 
C. tropicalis hexosaminidase enzyme (patent pending). 
Fifty (50) bacterial and 289 yeast strains as well as 61 mixed cultures 
were isolated on Candida ID (CAID), Albicans ID2 (AID2) and 
Sabouraud Gentamicin Chloraniphenicol (SGC). Growth and aspect 
of the colonies were monitored after 18-48 h of incubation. After 24 
h of incubation, colonies of 19 strains isolated on CAID and SGC 
were used to inoculate API 20C AUX, API Candida, ID 32C, Vitek 
YBC, Vitek2 ID YST and ATB Fungus strips. 
Growth on CAID is similar to that on AID2 and SGC for most 
of the yeast strains and even better for Cryptococcus neojormans. 
Selectivity for bacteria is superior on CAID, especially for strains with 
multiple resistance. Specificity of identification of C. albicans is signif- 
icantly increased, since none of the C. tropicalis strains is found to be 
false positive. With CAID, detection of mixed cultures is now easier 
than ever, with three perfectly distinct colors of colonies. Identific- 
ation and susceptibility testing on the various systems are not signif- 
icantly affected by isolation on CAID. 
Candida ID therefore allows the identification of C. albicans (even 
in mixed cultures) as well as the discrimination between C. glabrata 
and C. kwsei (white colonies) and between C. tropicalis, C. guillier- 
mondii, C. kefyr and C. lusitaniae. Complete identification and suscep- 
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tibility testing of the main yeast species in clinical specimens are 
obtained within 48 h. 
I P732 I Molecular epidemiology of Candida spp. 
isolated from ICU patients in a large district 
general hospital 
M. Kanellopoulou’, G. Stamos’, M. Savala2, I. I’etinneli’, D. 
Liakou’, NJ. Legakis’, A. Velegraki’, A. Mitroussia2, E. 
Papafragas’ . ‘Microbiology Departnient, Sismanoglion Districf General 
Hospital, N Erythrea, ’Department of Microbiology, Mytolqqy R+wrcc 
Laboratory, Medical School, llriitwsity of Athens, Athens, Greece 
The objective of this study was to explore whether certain subtypes 
of Candida spp. infect patients in the same ICU over a period of 1 
year. Fifty isolates froni either colonized or infected patients were 
studied. Susceptibility to antifungal agents and correlation with 
response to treatment were also examined 
All yeasts isolated from bronchial secretions, urine, blood, pus, 
CSF and intravenous catheter were initially plated onto the chro- 
inogenic substrate ALBICANS iD 2 (UioMCrieux) in order to screen 
for C .  albicatis. All isolates, including those that grew as blue colonies 
on the medium, were identified by their carbohydrate assimilation 
profile with the API ID 32C system (BioMkieux). Susceptibility to 
antifungal agents was determined by the NCCLS microdilution 
reference method (1997) and typing was carried out by pulsed-field 
gel electrophoresis following restriction of the total DNA with .SfiI 
(NEB, Biolabs, UK). 
Candida albicanr comprised the majority of the isolates (42%). 
Rapid presumptive identification of C .  albicans was greatly facilitated 
by the chromogenic substrate. Other Candida spp. such as C. glabrata, 
C. tropicalis and C. parapsilosis were isolated at lower frequencies. The 
majority of C. albicans isolates from patients admitted at the same time 
in the ICU and remaining there for the same period of time were of 
a homogeneous subtype. In contrast, some heterogeneity was 
detected among strains of C. glabrata and C. tropicalis, which did not 
correlate well with the hospitalization time of the patients. I t  is 
concluded that the Sji1 restriction patterns can be used for the mole- 
cular discriniination of C. albicans isolates. 
1-1 Epidemiology of yeast colonization in the 
intensive care unit (ICU) 
S. Heddenvick, M. Lyons, M. Liu, J. Vazquez, C. Kauffman. 
VAMC, lhiiversify qf Mirhi~qm F Mhyne State University, Michipn, 
CJSA 
Objectives: To study the epidemiology of yeast colonization and 
transmission of yeast strains in the ICU. 
Methods: We studied 63 ICU healthcare workers (HCW) and 
194 patients (pt) for 6 months. Pt oropharynx (OP) and rectum and 
HCW OP and hands were cultured twice weekly Yeast strain sin% 
larity was determined using contour clamped hoinogeneous electric 
field (CHEF) electrophoresis and random amplified polymorphlc 
DNA (RAPD) techniques. 
Results: 142 (73%) pt were colonized by yeasts. C. albirans was 
niost frequently recovered, followed by C. ,qlabrata and C. parapsilosir. 
Only 16 (17%) pt acquired yeast colonization after entry to the ICU. 
Of92  pt with =3 cultures pecforined, 51 were persistently colonized; 
30140 remained persistently colonized by their own strain of C. albi- 
cans or C. glabrata. O f  63 HCW, 42 (67%) were colonized by yeast; 
the most common was C. albimts ,  but C. parapsilosis predominated 
on hands (8.4%). Only 6 HCW had pcrsistent colonization of OP 
and none had persistence on hands. 15 of 126 (12%) pt and HCW 
who were epidemiologically linked carried the same C. albicam- strain, 
providing evidence for cross-transrnission of this species in the ICU. 
N o  link was found between HCW pt interactions and coloniz~ition 
with C. glabrata or C. parapsilosis. 
Conclusions: This report provides evidencr for transmission of 
C. nlbicans between HCW and pt in 3 non-outbreak setting in the 
ICU. 
lp7351 Possible role of fluconazole (FLU) in the 
treatment of candida and cryptococcus 
osteomyelitis (OM) 
L. Pittrow, A. Penk. Pfizer GmbH, Karlsrulze, Cerrnany 
Objectives: To define the clinical role of FLU in the treatment of 
candida and cryptococcus OM. 
Methods: Clinical data of 24 patients (pts) with proven O M  
caused by Candida spp. or Cryptorocmr neoformanc subsequently 
treated with FLU were analyzed with regard to both efficacy and 
tolerability. 
Results: 24 pts with a proven diagnosis of C h d i d a  spp. or Crypto- 
coccus neqfirmans OM were treated with FLU at a dosage of 200400 
mg (maximum dose: 1200 mg/day) for an average duration of 4 
months (maximum duration: 14 months). The highest cumulative 
FLU dose was 240 g (800 mg/day for 10 months). Most frequently 
presented locations of infection: vertebra (10 pts, 41.7%), costo- 
chondral region (2 pts, 8.3%), and femur, maxilla, os zygomaticum, 
pelvis, metatarsal bones, and sternum (1 patient each, 4.2%). The 
most frequent causative agent was C. albicans (15 pts, 62.5%)). 19 pts 
(79.2%) underwent additional surgical therapy. Long-term cuppres- 
sive therapy with FLU was necessary in 5 pts (20.8’%1). FLU was efftc- 
tive in combination with surgical therapy in 14/17 pts (82.3%) and 
as inonotherapy in 6/7 pts (85.7%~). FLU was well tolerated in all pts. 
Conclusions: FLU both alone and in combination with surgical 
therapy might play a role in the treatment of candida and crypto- 
coccus OM. 
(p7361 Continuous renal replacement therapy requires 
dosage adjustment of fluconazole 
L. Pittrow, A. Penk. @zer GnzbH, Karlsrrrlzr, Ciermnny 
Objectives: To investigate the pharmacokinctlcs of fluconazole (in 
Germany, fluconazole is approved for treatment of 1ifc-thrt.ateniog 
infections caused by Candida spp. and Cryptorocnrs rieoformans at a 
dosage of up to 800 mg/day) durmg continuouE heiiiofdtrdtion 
(CAVH, CVVH) and hemodialysis (CAVHD, CVVHU) to derive 
dosage recommendations. 
Methods: The elimination of fluconazole WAS studied in 8 
patientc with acute renal failure undergoing CVVH, CVVHI) 1 L/h, 
CVVHD 1.5 L/h, and CVVHD 2 L/h. Fluconazole 200 rng once 
daily and 2x400 mg/day was given 1V and plasma concentrations 
were measured up to 24 h after administration. 
Results: Plasma concentrations varied considerably among these 
procedures, with CVVHD, depending on the combined di.ily\ate/ 
ultrafiltratr flow, being superior to C W H  in removing fluconazolc. 
As fluconazole has a low protein binding rate of 10’% and a niolecu- 
lar mass of 306 Da, i t  was removed to a large extent from the plasil~a 
within 24 h. 
Conclusions: To achieve therapeutic plasma levels of fluconazole 
during continuous renal replacement therapy m vital indicationc, the 
sanie loading dose as in patients without renal failure should be 
applied, followed by the adjusted maintenance dose for anuric 
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patients, multiplied by a factor-based on theoretical considera- 
tions-taking the extracorporeal elimination of the absorbed dose 
into account (CAVH/CVVH: X2.2; ultrafiltrate flow 0.5 L/h; 
CAVHD/CVVHD: X 3.8; combined dialysate/ultrafiltrate flow 1.5 
L/h). Drug monitoring is recommended. 
rP737] High-dose fluconazole, corresponding plasma 
and tissue concentrations and clinical outcome 
A. Penk, L. Pittrow. Pfizer GmbH, Karlsruhe, Germany 
Objectives: To evaluate a correlation between dosage and plasma 
and tissue concentrations of high-dose fluconazole (in Germany, 
fluconazole is approved for treatment of life-threatening infections 
caused by Candida spp. and Cryptococcus neDfrmans at a dosage of up 
to 800 mg/day) and clinical outcome in patients with severe yeast 
infections. 
Methods: Clinical data of more than 500 patients with systemic 
candidiasis and cryptococcal infections treated with fluconazole up 
to 2000 mg/day were analyzed for improved clinical outcome due to 
increased dosages. 
Results: A strong relationship between fluconazole dosage and 
clinical response rates was found. In two subgroups of patients treated 
with fluconazole at a dosage ofeither 5 or 10 mg/kg BW, the higher 
response rate of 83% in the 10 mg/kg BW group was not biased by 
the severity of the underlying diseases. There was also evidence that 
interpretive breakpoints (S<8 pg/mL; S-DD 16-32 pg/mL; R 64 
pg/mL) derived from MICs could reliably predict clinical outcome: 
therapeutic success depended considerably on corresponding 
fluconazole plasma and tissue levels that were sufficiently higher than 
in vitro MIC values. In a subgroup of 39 neutropenic patients with 
hemato-oncologic malignancies, however, a dose-dependent response 
was not observed. 
Conclusions: Therapeutic response depends substantially on 
fluconazole plasma and tissue levels that are sufficiently above in vitro 
MIC values with respect to the individual immunologic status. 
[p7381 Clinical efficacy of fluconazole (FLU) alone or in 
combination with surgical therapy in the 
treatment of fungal arthritis (FA) complicating 
systemic mycoses 
A. Penk, L. Pittrow. @rer GmbH, Karlsruhe, Germany 
Objectives: To examine the clinical efficacy of FLU (in Germany, 
fluconazole is approved for treatment of life-threatening infections 
caused by Candida spp. and Crytococcus neDfrmnns at a dosage of up 
to 800 mg/day) alone or in combination with surgical therapy in FA 
complicating systemic mycoses. 
Methods: Clinical data of 30 patients (pts) with proven FA subse- 
quently treated with FLU were analyzed. Efficacies of both systemic 
antifungal and surgical therapy were evaluated. 
Results: 26 pts (86.7%) with native and 4 pts (13.3%) with pros- 
thetic arthritis with a proven fungal diagnosis were treated with FLU 
at a dosage of 200-400 mg (maximum dose: 800 mg/day for 6 
months (mean maximum duration: 2 years). FA presented as 
rnonarthritis in all pts with gonarthritis as the most frequent (13 pts, 
43.3%). Candida was the most frequently identified causative agent 
with C. albicam (10 pts, 33.39'4, Candida spp. not further specified (9 
pts, 30%), C. parapsiloris (3 pts, l0%), and C. tropicalis (2 pts, 6.7%). 
23 pts (76.7%) underwent additional surgical therapy. Long-term 
suppressive therapy with FLU was necessary in 4 pts, FLU was well 
tolerated and effective in combination with surgical therapy in 14/16 
pts (87.5%) and as monotherapy in 11/14 pts (78.6%). 
Conclusions: FLU both alone and in combination with surgical 
therapy is safe and effective in the treatment of FA. 
Study of incidence of mixed yeast cultures and 
fluconazole resistance in yeasts isolated from 
hospital and community patients 
M.G. Holliday, G.R. Short, K.E. Orr, EK. Gould. Minobiolon 
Department, Freeman Hospital, Newcastle, UK 
Objectives: To establish a collection of yeasts isolated from routine 
clinical samples from community and hospital patients, including 
solid organ transplant patients, and determine the proportion of 
mixed cultures, identity of isolates and fluconazole MICs. 
Methods: 744 routine clinical samples were cultured onto CHRO- 
Magar Canhda. All isolates were speciated by germ tube or API 
Candida. Fluconazole MICs were performed on isolates using Etests. 
Results: Yeasts were isolated from 194 (26%) samples, 11 ofwhich 
grew mixed cultures. Breakdown of isolates was as follows: C. albi- 
cans 6496, C. glabrata 14.2%, C. parapsilosir 6.6%. C. tropicalis 4.9%. C. 
krusei 1.6%, C. inconspima l.l%, C. famata 1.2%; Saccharomyces cere- 
visiae and Rhodotorula rubra accounted for < 1 each. C. albicans and C. 
flabrata together made up 8 of the mixed cultures. Yeasts were isolated 
from 32.5%, 26.5% and 15.8% of clinical specimens from hospital 
inpatients, community patients and solid organ transplant patients 
respectively. One of 69 C. albicans isolates had a fluconazole MIC of 
1.5 mg/L (256 mg/L), whereas 9 of 16 C. glabrata had MICs of 8 
mg/L and one C. krusei had an MIC of 64 mg/L. The remaining 
isolates had MICs of <2 mg/L. 
Conclusions: C albicans was the most frequent isolate, followed 
by C. glabrata. The presence of C. glabrata in the majority of mixed 
cultures and the high prevalence of fluconazole resistance in this 
species highlights the need for surveillance cultures in the immuno- 
compromised and for diagnostic laboratories to differentiate between 
Candida species where antifungal therapy is indicated. 
Various molecular mechanisms contribute to 
fluconazole resistance in Candida albicans 
M. Ruhnke, R. Franz, J. Morschhauser. Charite Campus Virchow 
Klinikum, Berlin; Zentrum fiir Infektiomfrschung, Wiirzburg, Germany 
Objectives: Serial Candida albicans isolates from recurrent episodes 
of oropharyngeal candidiasis (OPC) in six AIDS patients which 
became fluconazole resistant during therapy were analyzed by mole- 
cular methods. 
Methods: For molecular typing, hybridization with the CARE- 
2 probe was used. Expression of resistance genes (MDK1, CDR1/ 
CDR2) was performed using northern blot techniques. 
Results: The CARE-2 fingerprint patterns of the isolates demon- 
strated that in all six patients a previously susceptible strain developed 
fluconazole resistance. In two cases resistance correlated with 
enhanced expression of genes encoding multiple drug resistance pro- 
teins that mediate active drug efflux. Enhanced mRNA levels of the 
CDRI/CDRZ genes encoding ABC transporters were observed in 
fluconazole-resistant isolates from one patient as compared to the 
corresponding susceptible isolates. The fluconazole-resistant isolates 
from another patient exhibited high mRNA levels of the MDRI 
gene encoding a membrane transport protein of the major facilitator 
superfamily that was not detectably expressed in any of the flucona- 
zole-susceptible isolates. In the isolates from a third patient, increased 
MDRI mRNA levels and the change from heterozygosity to 
homozygosity for a mutant form of the ERG 16 gene correlated with 
continuously decreased drug susceptibility. 
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Conclusions: These results demonstrate that different molecular 
n~echanisnis may contribute to a gradual development of fluconazole 
resistance in C. albicam. 
m] Disk diffusion method versus Etest in 
antifungal susceptibility testing to fluconazole 
in yeasts isolated from cancer patients with 
fungemia 
I. Krupovi', J. Trupl', A. Kunovi', V. KrcniCry Jr'. 'Deparfmenf o j  
Pharniacolo'qy, Sckool o f  Public Health, University of Trnaua, Fnaua, 
'Department o f  Microbiolopy, Nafional Cancer Institute, Bratislava, 
Slovakia 
Objectives: Antifungal susceptibility in cancer patients did not 
correlate with the clinical outcome in cancer patients. 
Methods: Despite this fact, two inethods of antifungal suscepti- 
bility testing, Etest and the disk diffusion method (MIC according to 
NCCLS 27-MP) (DDM), were compared by thEtesting of83  strains 
of yeasts isolated from blood cultures from cancer patients with 
fungemia in 1997-98, hospitalized in the National Cancer Institute. 
Results: 47 C. albicans, 14 C. glabrata, 6 C. tropicah, 8 C. kmsei, 
1 C. pseudotropicalis. 1 C. mgosa, 1 C. reylanoidcs, 1 Cryptococcus lauren- 
tii, 1 Trirhospornn c ~ t ~ n ~ u i n ,  I Hamenula anomala, 1 Geotricktrm 
candidum and Pirhia okmeri werEtested. Six strains did not show any 
growth wholEtested with Etest (non-Candida yeasts). In the remaiii- 
ing 77 strains, of equal susceptibility, resistance was observed accord- 
ing to prepared breakpoints according to the NCCLS (1997: sensitive 
<MIC 8.0 nig/L, intermediate 16-38 mg/L, resistant 64 mg/L) and 
Etest manufacturer (AB Biodisk). O f  83 strains, only 5 were flucona- 
zole (FLU) resistant (3 C. kmsei, 1 C, zcylanoides, 1 Crypfocorcur lanrerc- 
tii with MIC 64 mg/L by disk diffusion and 32 for 1 C. krusci and 
256 ing/niL for C. reylanoides and C. laurentii]. 
Conclusions: One strain of Geotrirkum candidum (MIC 128 mg/L 
by DDM) and 4 strains of C. kwsei (MIC 64 by DDM and 32 by 
Etest) were classified as intermediately resistant. The other 73 yeasts, 
including 14 strains of C. ,qlabrata (MIC 2-12 by DDM and 4.0 by 
Etest) and 1 C. krirsei, were susceptible to fluconazole. 
Aspergilius terreus: an emerging pathogen in 
Kuwait 
Z.U. Khan, M. Kartom, J.I? Selvan, T.D. Chugh, K. Chandy. 
Dcpartmrnt of Microbiology, Faculty uf Medicine, Kuwait University; 
Department $Medicine, Mubarak Al-Kabeer Hospital; Department oJ 
Pcdiafric Cnrdiuloq, Ckcst Diseases Hospital, Kuwait 
Objectives: To highlight the importance of A. terreus as an enierg- 
ing pathogen in Kuwait. 
Methods: Three cases ofasp~rgillosis due to A. terretrs, one each 
in a patient with Addison's disease (Case 1). diabetes mellitus (Case 
2) and cardiac abnorinality (Case 3) ,  are presented. The diagnosis was 
based on direct microscopy of clinical material and culture. 
Results: Case 1, a 70-year-old feniale with Addison's disease, 
treated with cortiqone and thyroxine for 30 years, developed rapidly 
fatal pulmonary aspergillosis with extensive bilateral involvement. 
Besides septate hyphae, many spherical niorphologic forms were seen 
in direct microscopy. Case 2, a 30-year-old male with history of 
diabetes niellitus and pulmonary tuberculosis, developed 'fungal balls' 
in the right and left apical regions. Case 3, a 20-month-old boy with 
cardiac abnormality, had undergone an invasive procedure; later he 
developed a large vegetation involving endocardium. All the three 
isolates were resistant to amphotericin B and flucoiiazole but suscep- 
tible to itraconazole (< 1 mg/L) when tested by Etest. 
Conclusions: The report underscores the growing importance of 
A. terrfirs in aspergillosis and suggests that its treatment should be 
guided by antifungal susceptibility test results. 
lp743) Evaluation of Etest for antifungal susceptibility 
testing of Aspergillus species: comparison with 
microdilution method 
B. Ener, S. Akcaglar, 0. Tore. Departmetit ef A4icrn6inlogy, 1:acttlty cf  
Medicine, University of U l u d q ,  Bursa, Turkcy 
Objectives: To evaluate the compai-ative usefulness of the Rest xiti- 
fungal susceptibility method for Asprgilkrs species isolated from inva- 
sive inycoses. 
Methods: In vitro antifungal susceptibilities of 48 Asppct&~tlkrs 
strains were Etcsted for amphotericin U and itraconazole. The 
NCCLS-approved iiiicrodilution reference method for yeast was 
adapted according to the recommendations, and the Etest antifungal 
susceptibility was determined according to the nianufacturer's 
instructions. Solidified KPMl1640 and Casitone agar were the two 
culture media for itraconazole but only KPMI-1640 was used for 
amphotericin B. MIC endpoints were determined after 48 h of incu- 
bation at 3 5 T  and the percentage agreements within t 1 dilution 
were found. Candida parapsilosis (ATCC 2201 9) and Candida kritrei 
(ATCC 6258) were used for quality control. 
Results: The level of agreen~ent of Etcst MICs with broth 
microdilution MICs was 86% for amphotericm B. There were no 
compatible data with itraconazole when using Casitone agar as a 
culture medium but there was 58% agreement with solidified RPMI- 
1640. In general, broader ranges of MICs and higher M I C ~ O  and 
MICw values were obtained by Etest for both of the drugs. 
Conclusions: Although Etest is an easy and reproducible method 
for determining antifungal susceptibilities of yeasts, there arc few 
comparative studies for the molds. Casitone agar is the recommended 
culture medium for the azoles, but dense growth obtained in this 
medium caused difficulties in determining MIC endpoints in thls 
study. Thus it is believed that when working with the molds, better 
agreement can be obtained by using solidified RPMI-1640, but a 
more extensive comparative evaluation should be undertaken to 
confirm these preliminary results. 
lp744( invasive pulmonary aspergillosis refractory to 
amphotericin B in a patient with persisting 
neutropenia: successful treatment with 
voriconazole 
S. Schoniger, A. Hildebi-and, A. Richer, L. Bergnann, W.V. Kern. 
Uniuersity Hospital and Medical Center, INm,  Gcrmany 
Inimunoconiproiiiised patients with invasive pulmonary aspergillosis 
(PA) have 3 poor outcome, in particular when there is prolonged 
severe neutropenia and when effective therapy is not instituted early. 
We describe the case of a 59-year-old female patient with AML who 
developed pulmonary infiltrates in the right middle and lower Iobc 
suggestive of IPA. Asper;yillus f i im@zfus could be isolated repeatedly 
from sputum. Over a 6-week period of therapy with amphotericin 
B (AinB; daily dosage I ing/kg) there was radiographically docu- 
mented progression of the pulmonary infiltrates with development of 
new infiltrates in the left upper lobe after granulocyte recovery. 
Sputum cultures remained positive for Aspeyilkis, and the patient 
developed hemoptoe. Voriconazole (UK-I 09,496; a new azole) was 
started as an intravenous infusion (daily dosage: loading with 2 x 6  
nig/kg, then 2 X 4 nig/kg) and continued orally aher 1 week at a daily 
dose of 2 X200 ing. Radiographic and clinical improvcn~ent was 
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observed within 2 weeks. The patient remained on voriconazole 
maintenance treatment for 11 months, during which time 
chemotherapy-refractory leukemia with persisting neutropenia 
(<200 ceWpL) developed. Follow-up C T  scan at 6 and 11 months 
showed minimal residual lesions but no pulmonary infiltrates. There 
were no adverse events related to voriconazole. Susceptibility testing 
indicated MICs of 1.0 mg/L for AmB, and of 0.25 mg/L for 
voriconazole. Voriconazole may be a valuable alternative to A d  for 
IPA. The potential of an effective, well-tolerated oral maintenance 
therapy is a major advantage in patients with long-term neutropenia. 
Aspergillosis of the small bowel with 
secondary dissemination 
S. Schoniger, D. Bunjes, T. Mattfeldt, L. Bergmann, F! Kern, XV. 
Kern. University Hospital and Medical Center, Ulm, Germany 
Aspergillosis is a potentially fatal infection usually presenting as respi- 
ratory tract infection including the sinuses, trachea and/or lungs. The 
organism is a common environmental contaminant, sometinies lead- 
ing to a high concentration of airborne spores. A few reports have 
shown contamination of water or food with Aspergillus associated 
with the intestinal tract as portal of entry and primary focus ofhuman 
disease. Such an unusual case of invasive small bowel aspergillosis with 
secondary dissemination is described. A 49-year-old male patient 
developed abdominal pain a few weeks following allogeneic blood 
stem cell transplantation for CML Clinical examination and imaging 
studies indicated small bowel subileus. Endoscopy results of the upper 
intestinal tract and large bowel were non-diagnostic. Rotavirus anti- 
gen was detected in the feces. A presumptive diagnosis of subilieus 
due to distal jejunal stenosis possibly subsequent to radiation and 
rotavirus superinfection was made, and symptomatic treatment was 
started with little improvement. A few weeks later the patient devel- 
oped high-grade fever, bone marrow hypoplasia and severe pain in 
the left hip with radiologic signs of coxitis. Differential diagnosis 
included a reactivation of an earlier destructive hip tuberculosis. 
Blood cultures and ramographic studies of the chest including a C T  
scan were non-diagnostic. Necrotizing stomatitis developed with 
greyish pseudomembranes that repeatedly revealed pure cultures of 
Aspergillus furniptatus. The patient then underwent laparotomy with 
resection of a 30-cm stenotic part of the jejunum. The histopatho- 
logic diagnosis was invasive small bowel aspergillosis. Rapid dissem- 
ination of the aspergillosis with involvement of the lungs and brain 
despite therapy led to the death of the patient. 
ml ltraconazole resistance of Aspergillus spp. in 
a murine model of disseminated aspergillosis 
E. Dannaoui', E. Borel', E Persat', E Symoens', S. Picot', 
M.A. Piens'. EBGA Network(2-8) (European research group on 
Biotypes and Genotypes of Aspergillus fumigatus). European 
Concerted Action no BMH4-CT-97-2481, 1997-2000. 
Coordonator: Renee GRILLOT(2) 1 Parasitologie-Mycologie 
Medicale, Universitk LYON I (FR) : Piens MA, Dannaoui E, 
Perraud M, Monier MF, et Information Medicale, LYON : 
Chapuis F, 2 Parasitologie-Mycologie MCdicale et Moleculaire, 
GRENOBLE (FR) : Grillot R, Lebeau B, Burnod J, 3 Scientific 
Institute of Public Health BRUXELLES (BE) : Nolard N, 
Symoens F, Goens K, Heinemann S, 4 Immunologie-Parasitologie, 
Facult6 de Pharmacie, MONTPELLIER (FR) : Bastide JM, MalliC 
M, Caste1 D, Berthou S, Renaud F, De Meeus T, 5 Instituto de 
Igiene, MILAN (IT) : Viviani MA, Tortorano AM, Roverselli A, 
Coghati M, 6 Microbiology, University of LEEDS (UK) : Evans 
GE, Barton R, Ashbee R, Hopwood V, 7 Microbiology, 
University of NIJMEGEN (NL) : Meis F, Voss A, Verweij PE, 
Donnelly JP. 8 Mycologie, Faculte de Pharmacie LYON (FR) : 
Villard J, Carlotti A, Chaib F, Couble A, Casoli A 
Objectives: To evaluate in a murine model of aspergillosis the in 
vivo efficacy of itraconazole (ITZ) against different Aspergillus spp. 
isolates 
Methods: A murine model of disseminated aspergillosis was used. 
Mice were infected intravenously with a calibrated spore suspension. 
Preliminary studies were performed to determine the LD9a% for each 
strain. ITZ was adrmnistered for 10 consecutive days starting 2 h after 
infection. Drug efficacy was assessed by determining delay in morta- 
lity and organ burdens. Two A. fumigatus isolates were tested IHEM 
9900 susceptible to IT2 in vitro (SITZ) and AF 1422 resistant to ITZ 
in vitro (RITZ). Two referenced ITZ-resistant strains (Denning et d, 
J Antinlicrob Chemother 1997; 40: 401-14) were used as controls. 
ITZ-susceptible and -resistant A .  terreus isolates were also tested 
Results: In vitro susceptibility and in vivo outcome for reference 
strains were similar to those previously published. IHEM 9900 
(SITZ) was susceptible in vivo and for AF 1422 (RITZ) the in vitro 
resistance was confirmed in vivo. Similar results were obtained for A. 
terreus isolates, with a correlation between in vitro resistance and in 
vivo outcome 
Conclusions: We showed that the resistance of Aspergillus spp. to 
ITZ could be detected in vitro and could be confirmed in vivo in a 
murine model of disseminated aspergillosis. These results suggest that 
in vitro susceptibility testing of clinical Aspergillus isolates is appro- 
priate. This work was also supported by a grant from Pfizer, Orsay, 
France. 
[p746( Use of a new chromogenic medium for 
isolation of fungi from clinical samples 
H. Fricker-Hidalgo, B. Lebeau, H. Pelloux, P. Ambroise-Thomas, 
R. Grillot. Service de Pnrasitologie-Mycoloie, Center Hospitalier 
Universitaire, Grenable, France 
Objectives: Candida ID (CAID, bioMerieux) is a new plated 
medium for isolation of fungi, direct identification of Candida albi- 
tans (blue colonies) and discrimination of other Candida species @ink 
and white colonies). CAID was compared with AIbicans ID2 (AID2) 
and Sabouraud Gentamicin Chloramphenicol (SGC). 
Methods: Two hundred and twenty clinical samples were seeded 
simultaneously on the three media (CAID, AID2 and SW). Growth 
and aspect of colonies were monitored after 24, 48 and 72 h. 
All colonies showing different morphologies were identified using 
conventional mycologic methods including agglutination tests 
(Bichrolatex albicans test and Krusei color, Fumouze) and the ID 
32C system (bioMerieux). 
Results: Among the 143 identified species (101 positive samples), 
139/143 (97.2%) fungus species were isolated and identified on 
CAID, 1321143 (92.3%) on AID2 and 123/143 (86.0%) on SW. A 
98.6% sensitivity (72 among 73 Candida albicans identified by 
Bichrolatex albicans) and a 100% (70/70) specificity were observed 
in the identification of Candida albicnnr isolates on CAID. The 
numbers of fungal isolates appearing after 24 h of incubation were 
95 on CAID, 105 on AID2 and 100 on SW, and after 48 h of incu- 
bation 135 on CAID, 132 on AID2 and 122 on SW. 
Conclusions: This comparative study showed that, even if the 
colonies were smaller on CAID than on SW, CAID was able to allow 
the isolation and the identification of more fungus species than SGC 
and AID2, because of the higher reliability of CAID for the discrim- 
ination of species in mixed cultures. 
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v1 Molecular-based monitoring for fungal 
infections in liver transplant recipients (LTR) 
S. Neuburger, N. Rayes, P. Neuhaus, M. Ruhnke. Charit6 C a m p ~ s  
Virclrow Klinikum, Berlin, Cerniany 
Objectives: Fungal infections in LTR during the first few months 
after transplantation are important causes of morbidity and mortality. 
Methods: 224 EDTA blood samples (BS) from 28 LTR (14 
female/l4 male, mean age 49.9 years) were analyzed during hospi- 
talization (1-14 weeks, mean 4.8 weeks). After rapid DNA extrac- 
tion with Dynabeads we worked with a PCR-based assay according 
to Einsele et a1 fJCM 1997; 35:1353-60) to rapidly detect fungal 
DNA from positive (+) BS. The assay used a fungu-specific, univer- 
sal primer for DNA amplification with subsequent species-specific 
hybridization. 
Results: 60/224 BS (26.8%) had (+) PCR signals. 21/28 patients 
had one or more PCR resultr (1-5, mean 2.1). Mostly, BS were 
found to be (+) at the time of transplantation (14 BS) or transplant 
rejection (11 BS). Culture-proven invasive fungal disease ( fatal 
candida septicemia) was found in 1/21 patients with (+) PCR results. 
This patient was repeatedly PCR (+) 7 days before detection of 
Caridida albicans in blood culture. 13 (+) BS correlated with clinical 
sign? (fever, leucocytosis, CRPT) but no proven fungal infection. 7 
patients were negative throughout the whole hospital stay. 2 patients 
received pre-emptive therapy with aniphotericin B for ruspected 
fungal infection; after settling of therapy they were PCR (+) (4BS) 
without culture-proven fungal infection. 
Conclusions: This temporary result of our study which is still in 
progress showed that this method may be helpful for individual 
patients. 
Fungal corneal infections: emerging species 
and antifungal susceptibility trends 
D. Petropoulou’, I. Dolapsaki’, K. Masselou’, A. Mitroussia’, NJ. 
Legakis’, A. Velegraki’. ‘Microbiology Laboratory, National Rubella 
Reference Center, District Genera/ Hospitd ‘ C .  Gennirnatas’, 
’Department qf Microbiolqx Mytolofl Refrenre Laboratory, Medical 
School, University ofAthens, Greece 
Fungal keratitis has a diverse geographic distribution and it is gener- 
ally associated with ocular trauma, previous topical corticosteroid 
therapy and contact lens use. The purpose of this 1-year prospective 
study was to identify the fungal species implicated in eye infections 
in our hospital and to determine antifungal susceptibility. 
Sixty-seven consecutive sampler from corneal scraping of patientr 
in the Athens University Eye Center were cultured on standard 
microbiological media and stained smears were microscopically 
examined for bacteria and fungi. Yeast isolates were identified by the 
API ID 32C (BioMCrieux) system and filanientous fungi were iden- 
tified to the species level by a series of physiologic and biochemical 
tests. Minimum inhibitory concentrations (MICs) of amphotericin 
B, 5-fluorocytocine, fluconazole, itraconazole and ketoconazole were 
determined on casitone agar using Etest (AB Biodisk, Sweden). 
Grani-negative bacteria comprised the majority of the isolates 
(52). Candida alhicans (3, C. ciJrii (2) .  C. ,ylabrata ( l ) ,  Cryptocoicus 
albidus ( l ) ,  Aspe~gil/nsfnm(yatus (2), Acremonbm stricturn (l), Firsarium 
oxyspornm (3) and Drcrkslera kauuiiensis (Helmitzfhosporinm bipolaris) 111 
were isolated. Two patients presented with both bacterial and fungal 
ocular infections. An increased MIC of amphotericin B (1 pg/niL) 
was recorded for Fusarinm and Acremoniirm spp. A fluconazole MIC 
of 16 pg/niL (sensitive dose dependent) was recorded for C. ‘qlabrata. 
Resistance to fluconazole was recorded for all filamentous fungi. 
This is the first report of documented infective keratitia Attribut- 
able to H. bipolaris. Accurate identification of fungal pathogens and 
susceptibility data are useful in selecting the appropriate systemic and 
topical antifungal chemotherapy for the management of ocular fungal 
infections. The clinical outcome of the cases presented here confirms 
that pertinent initial and maintenance therapy can help to avoid thrr- 
apeutic penetrating keratoplasty. 
)p749/ Differential diagnosis of Trichosporon asahii 
from Cryptococcus neoformans and Candida 
spp. by a single PCR-REA from clinical material 
A. Velegraki’, M. Kanellopoulou’, M. Logotheti’, G. StamoF‘, E. 
Papafragas’, A. Mitroussia’ , N.J. Legakis’ . ‘Departntent of 
ih’icrohiolqy, Mycology R<ference Laborarory, Medical School, Uniiwrsity 
of Arlictis, ‘Microbiology Depurtmmt, Sisrnanoglion Di5frici Gnitral 
Hospiral, ’Microbiology Department, Pediarrir Hospiral P G A. 
Kyriakuu, Athens, Greece 
The objective of this study was to test whether non-culture iiicthodc 
would facilitate rapid identification of Triclrosporon spp. directly from 
clinical specimens. This is essential, as differentiation of 7: nsakii from 
Cryptacoccirs weofrmans is of particular clinical importance becaure 
neutropenic patients with disseminated trichosporonous seldorn 
respond to amphotericin B and their serum latex particle agglutina- 
tion (LPA) test for C. neofoimans antigen is positive. Therefore, accu- 
rate identification is mandatory in order to administer promptly the 
appropriate antifungal chemotherapy. The present study was initiated 
upon isolation of two 1: asahii strains from blood cultures of patients 
in the ICU of the Sismanoglion General Hospital. The recognition 
of 1: asahii as an etiologic agent of trichosporonosis is reported for 
the first time in Greece. 
The strains were identified by their carbohydrate assimilation 
profile with the API ID 32C system (BioMerieux). Susceptibility to 
antifungal agents was determined by Etest (AU Biodisk, Sohia, 
Sweden) and DNA was extracted from spiked blood and CSF samples 
with XTRAX (Gull Laboratories, UT, USA). The oligonucleotide 
primers based on the internal transcribed spacer region$ of the organ- 
ism’s genome, ITS1 and ITS4, were used in the PCR reaction. These 
primers also amplify template DNA from Candida and Cryptocorcus 
spp., producing ainplicons of 500-600 bp. Differentiation of these 
three genera can be accomplished upon restriction of the aniplifica- 
tion product with MspI and EcoRI. Trirkospuroti asnkii produces 
distinct fingerprints on standard 2.5 agarose gels. 
This detection system, which is reported for the first time, can he 
a useful microbiological tool for the diagnosis of trichosporonosis 
within 24 h. 
m\ Comparison of the in vitro activities of 
voriconazole and other new triazoles with 
those of established agents 
A. Espinel-Ingroff. Departmwit II~ Internal Mediiine, Mcdiid CoIIi:(rc (!f 
Viqinia, Vitginia Commonwealth University, Richmowd, VA, I JSA 
Objectives: (1) To investigate the effect of germinated (C) verws 
non-germinated (NG) conidial suspensions on MICF of three ncw 
triazoles (voriconazole (V), BMS 207147 (U), SCH 56592 (S)), itra- 
conazole (I) and aniphotericin B (A) for Aspegi/lns spp. (2) To 
compare the in vitro activities of these triazoles to those of I and A 
against Aspeyillus spp. and emerging mold pathogens. 
Methods: MICs for 55 isolates of Aspeyillirs.flavus, A.  jinr@~tus, 
A. nidulans, A .  n i p r ,  A. sydowii, and A. tcrreus, and 28 strains of Air?- 
moniirm spp., Furarium spp., Scoprt/ariopsis krevirartlir and S‘rytn/iifrrrin 
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spp., were determined by the NCCLS broth microdilution method 
for conidium-forming filamentous fungi (M38-P document): stan- 
dard RPMI-1640 broth, G (Aspegillus spp.) and NG (Aspergillus spp. 
and emerging molds) conidial suspensions (-lo4 CFU/mL), and 48 
h of incubation at 35OC. MICs corresponded to approximately 50% 
or more (azoles) and complete growth inhibition (A). 
Results: Overall, MlCs of the five agents for the 55 Aspergillus 
spp, were the same or within 2 dilutions with NG and G inocula. 
The activities of the three new azoles were comparable (0.03-2 
pg/mL MC ranges) and superior to I (0.03-8 pg/mL MIC range) 
and A (0.5-4 pg/mL MIC range) for Aspegillus spp. The activities of 
the five agents were simdar for most of the emerging mold pathogens, 
but lower (0.01-4 pg/mL MIC ranges) than those for Aspetgillus spp. 
Conclusions: These in vitro data suggest the potential value of 
voriconazole and the other two new triazoles for the treatment of 
human mycoses caused by these molds. 
1 P751 1 Prevalence and antifungal susceptibility of 
vaginal Saccharomyces cerevisiae 
L. Pitzurra, M. Cesarini, M. Giammarioli, M. Giraldi, A. Sensini, 
M. Tristani, F. Bistoni. Microbiology Section, University o f  Perugia, 
.Peru&, Ztdy 
Objectives: To evaluate the prevalence and antifungal susceptibility 
of vaginal S. cerevisiae in women attending the Microbiology Unit of 
Perugia General Hospital. 
Methods: 1722 vaginal swabs were examined for genital tract 
yeast infection. Identification of S. cereuisiae was based on lack of 
germ-tube formation in human serum, absence of chlamydospore 
production, and results of carbohydrate assimilation profile tests. 
Susceptibilities to ainphotericin B, flucytosine, nystatin, miconazole, 
ketoconazole, econazole and fluconazole were evaluated by the 
NCCLS reference method. 
Results: In 381 (22%) patients, cultures were yeast positive. 
Candida albicans was the most frequently isolated species (73%) 
followed by S. cereuisiae (27%). Of patients positive for S. cereuisiae, 24 
were pregnant, 9 had a history of recurrent vulvovaginitis and vulvo- 
vaginal symptoms at sampling, and 5 had previously received multi- 
ple courses of antibiotics or fluconazole. All S. cereuisiae isolated 
showed a uniform degree of sensitivity to fluocytosine. Significant 
differences in susceptibility were observed with amphotericin B, 
nystatin and azoles. The highest degree of resistance was observed 
against ketoconazole and fluconazole. 
Conclusions: Vaginal colonization and symptomatic vaginitis due 
to S. cereuisiae, although rare, do occur. As S. cerevisiae isolates show 
variable resistance to azole antifungal agents, fungal cultures and anti- 
fungal susceptibility testing are valuable in confirming the diagnosis 
and selecting appropriate therapy. 
Solid organ transplants 
Im1 Cytomegalovirus diagnosis in BMT patients- 
comparison of NASBA, PCR and antigen 
immunofluorescence assay 
A. Reip, H. Meisel. Institute of Virofon, C h a d ,  Medical Schooi o j  
Humboldt University, Berlin, Germany 
Objectives: Investigation of the applicability of the CMV pp67 
mRNA detection method for reliable diagnosis of an active CMV 
infection and for the monitoring of antiviral therapy in coniparison 
to other routinely established CMV detection methods. 
Methods: More than 100 blood samples of 20 bone marrow 
transplant (BMT) recipients were tested for CMV pp67 mRNA by 
NASBA (NucliSens, Organon Teknika), CMV DNA by PCR (in- 
house), and CMV pp65 antigen by immunofluorescence test 
(CinaKit, Argene/Biosoft). The observation periods lasted up to 8 
months post-BMT. 
Results: In 12 samples of three BMT patients CMV pp67 mRNA 
could be detected. Seven out of 12 mRNA-positive samples were 
CMV pp65 antigen positive as well. In all tested samples, detection 
of CMV mRNA correlated with the presence of CMV DNA by in- 
house PCR. All of the CMV mRNA-positive patients showed clin- 
ical symptoms of an active CMV infection. Under successful 
ganciclovir therapy, the loss of CMV mRNA was observed before 
the disappearance of pp65 antigen and CMV DNA. 
Conclusions: In close-meshed follow-up ofBMT patients, CMV 
pp67 mRNA assay is a reliable diagnostic tool for early diagnosis of 
CMV reactivation or infection. The preliminary data let us suggest 
that this marker should be beneficial for the prediction of CMV 
disease in BMT patients. CMV pp67 mRNA detection allows the 
timely start of pre-emptive ganciclovir therapy and earlier prediction 
of the efficacy of antiviral therapy than pp65 antigen or CMV-DNA. 
lp7531 The use of CMV pp65 antigenemia assay for 
diagnosis and treatment of cytomegalovirus 
infection in kidney recipients 
A.S. Pacsa, S. Tarek, R.K. Gupta, K.V. Johny, M.R.N. Nampoory. 
Faculty of Medicine, Kuwait University and Organ Eansplant Center, 
Ministry o f  Health, Kuwait 
Objectives: Evaluation of the CMV antigenemia assay for: (a) diag- 
nosing ongoing CMV infections and (b) monitoring the effective- 
ness of ganciclovir therapy. 
Methods: CMV pp65 antigen-positive leukocytes were deter- 
mined in serial samples of 82 kidney recipients ofwhom 23 received 
ganciclovir therapy. 
Results: Forty-five (55%) of the patients had the antigen in their 
leukocytes. Among these patients, there were 35 with CMV-related 
clinical symptoms. With a cut-off level of 5 antigen-positive cells/ 
50 000, the assay had a 93% positive and a 96% negative predictive 
value. After 2 weeks of ganciclovir treatment, antigen-positive leuko- 
cytes decreased considerably (< 5/50 000). or disappeared 
completely. Parallel with the decrease of pp65 antigen-positive cells, 
patients became free of CMV-related symptoms. 
Conclusions: The CMV antigenemia assay is useful for both 
diagnosing CMV disease and monitoring the effectiveness of antivi- 
ral therapy in kidney recipients. 
(p7541 The NucliSens CMV PP67 assay is a good 
predictor test for CMV disease occurrence in 
renal transplant recipients 
B.M. Imbert, C. Zandotti, V. FerrC, B. Vollant, J. Gattepaille, S .  
Billaudel. Virofon  Laboratory, Biology Institute, Nuntes University 
Hospital, Nantes, France 
Objectives: To evaluate the biological and clinical relevance of 
CMV mRNA detection in whole blood by the newly available 
NucliSens CMV pp67 assay. 
Methods: Twenty-five consecutive renal transplant recipients 
were prospectively followed during the first 120 postoperative days 
for CMV infection and disease. At each follow-up timepoint (once 
a week or twice a month), four assays were performed: viremia was 
determined by detection of early antigens in PBLs, DNAemia in 
